Compare NCMI & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | ENTA |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.1M | 371.6M |
| IPO Year | 2006 | 2012 |
| Metric | NCMI | ENTA |
|---|---|---|
| Price | $3.98 | $12.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.63 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 295.4K | 158.2K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 52.17 | 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $11.20 | $7.76 |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $2.80 | $6.45 |
| 52 Week High | $5.03 | $17.15 |
| Indicator | NCMI | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 40.36 |
| Support Level | $3.74 | $11.92 |
| Resistance Level | $4.04 | $13.98 |
| Average True Range (ATR) | 0.16 | 0.70 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 74.36 | 7.38 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.